DERM

Over the past six months, Journey Medical Corp.'s stock (DERM) experienced several events. On March 25, 2026, the company reported Full-Year 2025 Financial Results, showing a 10% revenue increase to $61.9 million and Emrosi™ generating $14.7 million, which was followed by a 30.01% stock price decrease. On April 21, 2026, Journey Medical secured a contract with a major Group Purchasing Organization for Emrosi®, expanding access to approximately 85% of commercial lives, but the stock price decreased by 5.20%. On May 13, 2026, First Quarter 2026 Financial Results showed a 21% year-over-year revenue increase to $16.0 million, driven by Emrosi® revenues of $6.3 million, leading to a 22.35% stock price increase. On August 12, 2026, Second Quarter 2026 Financial Results reported a 23% year-over-year revenue increase to $18.5 million and Emrosi® revenues of $8.1 million, with a narrowed GAAP Net Loss, resulting in a 3.42% stock price increase. On August 17, 2026, a new minor risk of shareholder dilution was identified due to a 16% increase in shares outstanding. On September 8, 2026, the announcement of participation in September 2026 Investor Conferences was followed by a 6.52% stock price decrease. Overall, the stock price gained 0.6% over the past 12 months.